Port Charlotte, FL

Parkinson's Disease Treatment Center of SW Florida

Parkinson Disease

Shy-Drager Syndrome

Depression

Mental Disorders

Multiple System Atrophy

Psychomotor Agitation

Aggression

Psychotic Disorders

Depressive Disorder

Dementia

Safinamide

Levodopa

Dopamine

MP-101

CVN424

Pimavanserin

ONO-2808

MOTION

Newron Pharmaceuticals

Acadia Pharmaceuticals

Biotie Therapies

Cerevance

Mediti Pharma

Ono Pharmaceuticals

Supernus Pharmaceuticals

condition

Atrophy

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Parkinson's Disease Treatment Center of SW Florida | Port Charlotte, FL

Site insights

Work at this site?

Active trials

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Trial sponsors